Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Explore our webinars from expert dermatology speakers
If you or your colleagues weren’t able to join our webinars, recordings can be found below. We’ll continue to grow the collection, so keep checking back!
A2324 study: assessing the impact of tailored dosing of Cosentyx in patients ≥90kg
Research suggests that biologic efficacy is lessened in heavier-weight patients, an unmet need in this population. Professor Warren highlights the potential benefits that up-titrated Cosentyx dosing regimes have for adult PsO and PsA patients with concomitant PsO with a weight ≥90kg. The relevant posology for this dosing can be read below:
For the treatment of moderate to severe plaque psoriasis, the recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher.
BAD 2021 – Take control early: a complete approach to successful management of skin and joints in patients with moderate to severe plaque psoriasis (PsO)
Hear consultant dermatologists Dr Laura Savage and Dr Amy Foulkes as well as NIHR Clinician Scientist Professor Laura Coates share their approach to early management of skin and joint manifestations in patients with PsO.
They discuss the predisposition of PsO patients to PsA and current treatment recommendations. Efficacy, safety and head-to-head data for Cosentyx are also presented. Lastly, the panel discuss measurement of treatment success.
Joint clinics: combining dermatology and rheumatology care within your Trust
Watch UK-based experts dermatologist Professor Miriam Wittmann and rheumatologist Dr Helena Marzo discuss the importance of joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology-rheumatology clinics can be established within a Trust, and what advantages in managing patients they can offer. They then further discuss their experiences when setting up a joint clinic.
Treating plaque psoriasis (PsO) and psoriatic arthritis (PsA) patients with multiple manifestations
Watch consultant dermatologist Dr Christos Kasparis as well as NIHR Clinician Scientist Professor Laura Coates discuss the management of PsO and PsA patients with multiple manifestations and offer perspectives on the importance of timely screening and treating patients early with the correct biologic. The experts also describe the Complete Cosentyx (secukinumab) Approach*, discussing clinical trial evidence from MAXIMISE for PsA, and nail and scalp data.
Click here for Cosentyx®(secukinumab) prescribing information
Dermatology 2020: A virtual reality
In this virtual meeting series, a number of key experts gathered to discuss hot topics in dermatology, including the latest data in psoriasis. Hear from Dr Amy Foulkes on why you should watch more.
“Watch out for the latest real world evidence data from the BADBIR group, data from the EXCEED head-to-head trial, the updated BAD guidelines for 2020…”
*The Complete Cosentyx Approach is defined as efficacy in both skin and persistent nail and scalp psoriasis, as well as psoriatic arthritis and improvements in quality of life.
BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; GP, general practitioner; MRI, magnetic resonance imaging; MTX, methotrexate; NIHR, National Institute for Health Research; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.
